Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs Roundhill Magnificent Seven ETF (MAGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs Roundhill Magnificent Seven ETF — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $14.62 (market cap $6.04B), while Roundhill Magnificent Seven ETF trades at $73.73 (market cap $5.78B). The key difference: Iovance Biotherapeutics Inc. Common Stock and Roundhill Magnificent Seven ETF are close in size by market cap, and Iovance Biotherapeutics Inc. Common Stock is more actively traded (14,805,993 versus 4,410,665). Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and Roundhill Magnificent Seven ETF for 36 Days on average.
| IOVA | MAGS | |
|---|---|---|
Market Cap | $6.04B | $5.78B |
Volume | 14,805,993 | 4,410,665 |
Sector | Health | Sector/Thematic |
52-Week High | $14.82 | $73.90 |
52-Week Low | $1.81 | $55.39 |
Typical Hold Time | 0 Days | 36 Days |
Enterprise Value | $5.97B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
MAGS (Roundhill Magnificent Seven ETF) trades at $73.73, showing minimal daily movement with a 0.05% gain. Technical indicators signal a bullish trend with strong moving average support, while oscillators remain neutral. The ETF provides equal-weighted exposure to seven mega-cap tech leaders, though it has underperformed the broader market in 2026 with only 2% year-to-date gains compared to S&P 500 strength.
Outlook remains cautiously optimistic given AI-driven growth potential, but concentration risk and underperformance versus diversified indexes present challenges. Key risks include tech sector volatility and shifting investor preferences away from the Magnificent Seven theme toward broader market exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About Roundhill Magnificent Seven ETF
MAGS is an ETF that provides concentrated exposure to the seven technology-focused mega-cap companies often referred to as the 'Magnificent Seven' (Alphabet, Amazon, Apple, Meta, Microsoft, NVIDIA, and Tesla). The fund is designed to capture the performance of these market-leading stocks, which have been the primary drivers of market returns. It offers a simple way for investors to invest solely in this select group of high-growth technology companies.
Read more on MAGS →
